MedTrace Logo

QR052107B Tablets in Patients With Subacute Cough of Phase Ⅱ Study

NCT06920836 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2025-04-10

No results posted yet for this study

Summary

The purpose of the study is to Evaluate the Efficacy and Safety of QR052107B 100mg， QR052107B 400mg in Patients with Subacute Cough.

Conditions

Interventions

DRUG

QR052107B 100 mg

QR052107B 100 mg QD

DRUG

QR052107B 400 mg

QR052107B 400 mg QD

DRUG

Placebo

placebo QD

Sponsors & Collaborators

  • Wuhan Createrna Science and Technology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Ting Yang, MD · China-Japan Friendship Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-21
Primary Completion
2023-11-22
Completion
2023-12-25

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06920836 on ClinicalTrials.gov